drugset
drugset / Trial / NCT06145308

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

NCT06145308 ↗

Phase 2 Recruiting 39 enrolled Peking Union Medical College Peking University Hospital of Stomatology · collab
Non-randomizedParallel-groupSingle-blindTreatment

Summary

Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.

Timeline

Start
2023-08-15
Primary completion
2028-07-10
Completion
2028-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule 150 mg Oral
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject Alpelisib Small molecule 300 mg Oral
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Apalutamide Small molecule 240 mg Oral
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Bicalutamide Other / unclassified 50 mg Oral
Subject Cadonilimab Monoclonal antibody 10 mg/kg —
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Carboplatin Small molecule 75 mg/m2 Intravenous
Subject Carboplatin Small molecule 200 mg/m2 Intravenous
Subject Carboplatin Small molecule 250 mg/m2 Intravenous
Subject Carboplatin Small molecule 350 mg/m2 Intravenous
Subject Catequentinib Small molecule 12 mg Oral
Subject Cisplatin Other / unclassified 50 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Darolutamide Other / unclassified 600 mg Oral
Subject Disitamab Vedotin Monoclonal antibody 2.5 mg/kg Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject ESG401 Monoclonal antibody 16 mg/kg Intravenous
Subject Enfortumab Vedotin Other / unclassified 1.25 mg/kg Intravenous
Subject Entrectinib Small molecule 600 mg Oral
Subject Enzalutamide Other / unclassified 160 mg Oral
Subject Exemestane Small molecule 20 mg Oral
Subject Fluzoparib Small molecule 150 mg Oral
Subject Fulvestrant Small molecule 500 mg Intramuscular
Subject Goserelin Other / unclassified 10.8 mg Subcutaneous
Subject Iparomlimab Monoclonal antibody 5 mg/kg Intravenous
Subject Ivonescimab Monoclonal antibody 20 mg/kg Intravenous
Subject Larotrectinib Small molecule 100 mg Oral
Subject Lenvatinib Small molecule 8 mg —
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Leuprolide Other / unclassified 3.75 mg Subcutaneous
Subject Niraparib Small molecule 300 mg Oral
Subject Olaparib Small molecule 300 mg Oral
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Paclitaxel Small molecule 260 mg/m2 Intravenous
Subject Palbociclib Small molecule 125 mg Oral
Subject Pamiparib Small molecule 60 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Pertuzumab Monoclonal antibody 420 mg Intravenous
Subject Pertuzumab Monoclonal antibody 840 mg Intravenous
Subject Pyrotinib Small molecule 400 mg Oral
Subject Rivarutamide Unknown 240 mg Oral
Subject Rivoceranib Small molecule 250 mg Oral
Subject Sacituzumab Govitecan Monoclonal antibody 10 mg/kg Intravenous
Subject Sacituzumab Tirumotecan Other / unclassified 5 mg/kg Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Subject Trastuzumab Monoclonal antibody 8 mg/kg Intravenous
Subject Trastuzumab deruxtecan Monoclonal antibody 5.4 mg/kg Intravenous
Subject Tuvonralimab Monoclonal antibody — —
Subject Vebecotutamab Unknown 2 mg/kg —
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous

Indications

salivary gland carcinoma